Rajesh Krishnan

Insider Reports History

Location
San Diego, CA
Signature
/s/Chase C. Leavitt, Attorney-in-fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Rajesh Krishnan:

Company Role Class Num Shares Value Price $ Report Date Ownership
Oncternal Therapeutics, Inc. CTO/CSO Common Stock 44,019 $21,838 $0.4961 03 Jan 2024 Direct
Oncternal Therapeutics, Inc. CTO/CSO Stock Option 17,700 14 Feb 2024 Direct

Insider Reports Filed by Rajesh Krishnan

Symbol Company Period Transactions Value $ Form Type Role Filing Time
/report/000120919124003411-krishnan-rajesh-2024-02-14 Oncternal Therapeutics, Inc. 14 Feb 2024 1 $0 4 CTO/CSO 15 Feb 2024, 18:00
/report/000120919124000974-krishnan-rajesh-2024-01-03 Oncternal Therapeutics, Inc. 03 Jan 2024 1 -$5,873 4 Chief Technical Officer 05 Jan 2024, 16:00
/report/000120919123052014-krishnan-rajesh-2023-10-02 Oncternal Therapeutics, Inc. 02 Oct 2023 14 $0 4 Chief Technical Officer 04 Oct 2023, 16:59
/report/000120919123041312-krishnan-rajesh-2023-07-03 Oncternal Therapeutics, Inc. 03 Jul 2023 1 -$3,923 4 Chief Technology Officer 05 Jul 2023, 18:57
/report/000120919123012395-krishnan-rajesh-2023-02-21 Oncternal Therapeutics, Inc. 21 Feb 2023 1 $0 4 Chief Technology Officer 23 Feb 2023, 19:00
/report/000120919123002035-krishnan-rajesh-2023-01-03 Oncternal Therapeutics, Inc. 03 Jan 2023 1 -$6,363 4 Chief Technology Officer 05 Jan 2023, 17:00
/report/000120919122043737-krishnan-rajesh-2022-07-28 Oncternal Therapeutics, Inc. 28 Jul 2022 2 $0 4 Chief Technology Officer 01 Aug 2022, 18:20
/report/000120919122004581-krishnan-rajesh-2022-01-20 Oncternal Therapeutics, Inc. 20 Jan 2022 1 $0 4 Chief Technology Officer 24 Jan 2022, 15:00
/report/000120919122001976-krishnan-rajesh-2022-01-03 Oncternal Therapeutics, Inc. 03 Jan 2022 1 $0 4 Chief Technology Officer 05 Jan 2022, 18:00
/report/000120919121036323-krishnan-rajesh-2021-05-25 Oncternal Therapeutics, Inc. 25 May 2021 0 $0 3 Chief Technology Officer 27 May 2021, 18:06